Is Sunshine Biopharma, Inc. overvalued or undervalued?

As of 9 February 2023, the valuation grade for Sunshine Biopharma, Inc. has moved from does not qualify to risky. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.30, an EV to EBIT of 0.18, and an EV to EBITDA of 0.19, all indicating significant financial distress and inefficiency.
In comparison to its peers, Sunshine Biopharma's valuation is notably worse than that of Neurosense Therapeutics Ltd., which has a P/E of -6.98, and Cyclerion Therapeutics, Inc., which also holds a risky classification with a P/E of -3.02. The company's recent stock performance has been poor, with a year-to-date return of -52.33%, significantly underperforming the S&P 500's 2.44% return in the same period. This further reinforces the notion that Sunshine Biopharma is overvalued given its current financial standing and market performance.